nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2014 | Original Article

^99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres

verfasst von: Mattijs Elschot, Johannes F. W. Nijsen, Marnix G. E. H. Lam, Maarten L. J. Smits, Jip F. Prince, Max A. Viergever, Maurice A. A. J. van den Bosch, Bernard A. Zonnenberg, Hugo W. A. M. de Jong

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Radiation pneumonitis is a rare but serious complication of radioembolic therapy of liver tumours. Estimation of the mean absorbed dose to the lungs based on pretreatment diagnostic ^99mTc-macroaggregated albumin (^99mTc-MAA) imaging should prevent this, with administered activities adjusted accordingly. The accuracy of ^99mTc-MAA-based lung absorbed dose estimates was evaluated and compared to absorbed dose estimates based on pretreatment diagnostic ¹⁶⁶Ho-microsphere imaging and to the actual lung absorbed doses after ¹⁶⁶Ho radioembolization.

Methods

This prospective clinical study included 14 patients with chemorefractory, unresectable liver metastases treated with ¹⁶⁶Ho radioembolization. ^99mTc-MAA-based and ¹⁶⁶Ho-microsphere-based estimation of lung absorbed doses was performed on pretreatment diagnostic planar scintigraphic and SPECT/CT images. The clinical analysis was preceded by an anthropomorphic torso phantom study with simulated lung shunt fractions of 0 to 30 % to determine the accuracy of the image-based lung absorbed dose estimates after ¹⁶⁶Ho radioembolization.

Results

In the phantom study, ¹⁶⁶Ho SPECT/CT-based lung absorbed dose estimates were more accurate (absolute error range 0.1 to −4.4 Gy) than ¹⁶⁶Ho planar scintigraphy-based lung absorbed dose estimates (absolute error range 9.5 to 12.1 Gy). Clinically, the actual median lung absorbed dose was 0.02 Gy (range 0.0 to 0.7 Gy) based on posttreatment ¹⁶⁶Ho-microsphere SPECT/CT imaging. Lung absorbed doses estimated on the basis of pretreatment diagnostic ¹⁶⁶Ho-microsphere SPECT/CT imaging (median 0.02 Gy, range 0.0 to 0.4 Gy) were significantly better predictors of the actual lung absorbed doses than doses estimated on the basis of ¹⁶⁶Ho-microsphere planar scintigraphy (median 10.4 Gy, range 4.0 to 17.3 Gy; p < 0.001), ^99mTc-MAA SPECT/CT imaging (median 2.5 Gy, range 1.2 to 12.3 Gy; p < 0.001), and ^99mTc-MAA planar scintigraphy (median 5.5 Gy, range 2.3 to 18.2 Gy; p < 0.001).

Conclusion

In clinical practice, lung absorbed doses are significantly overestimated by pretreatment diagnostic ^99mTc-MAA imaging. Pretreatment diagnostic ¹⁶⁶Ho-microsphere SPECT/CT imaging accurately predicts lung absorbed doses after ¹⁶⁶Ho radioembolization.

Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A. Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers. Am J Clin Oncol. 2012;35:167–77.PubMedCrossRef

Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19:951–9.PubMedCrossRef

Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Intervent Radiol. 2009;20:1121–30.CrossRef

Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29:522–9.PubMedCrossRef

Lam M, Louie J, Iagaru A, Goris M, Sze D. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36:1320–8.PubMedCrossRef

Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors. Cancer. 2008;112:1538–46.PubMedCrossRef

Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494–500.PubMedCrossRef

Lam MG, Banerjee S, Louie JD, Abdelmaksoud MH, Iagaru AH, Ennen RE, et al. Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36:1536–47.PubMedCrossRef

Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Intervent Radiol. 2007;18:553–62.CrossRef

10.

Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial (90)yttrium-microspheres for inoperable hepatic-tumors. Int J Radiat Oncol Biol Phys. 1995;33:919–24.PubMedCrossRef

11.

Wright CL, Werner JD, Tran JM, Gates VL, Rikabi AA, Shah MH, et al. Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. J Vasc Intervent Radiol. 2012;23:669–74.CrossRef

12.

Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic Y-90-microspheres. J Nucl Med. 2000;41:1673–81.PubMed

13.

Slauson DO, Hahn FF, Benjamin SA, Chiffelle TL, Jones RK. Inflammatory sequences in acute pulmonary radiation-injury. Am J Pathol. 1976;82:549–72.PubMedCentralPubMed

14.

Yorke ED, Jackson A, Rosenzweig KE, Braban L, Leibel SA, Ling CC. Correlation of dosimetric factors and radiation pneumonitis for nonsmall-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:672–82.PubMedCrossRef

15.

Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293–8.PubMed

16.

Kennedy AS, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13–23.PubMedCrossRef

17.

Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947–52.PubMedCrossRef

18.

Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31:431–8.PubMedCrossRef

19.

Yu N, Srinivas SM, DiFilippo FP, Shrikanthan S, Levitin A, McLennan G, et al. Lung dose calculation with SPECT/CT for 90yttrium radioembolization of liver cancer. Int J Radiat Oncol Biol Phys. 2013;85:834–9.PubMedCrossRef

20.

Elschot M, Vermolen BJ, Lam MG, de Keizer B, van den Bosch MA, de Jong HW. Quantitative comparison of PET and bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS One. 2013;8:e55742.PubMedCentralPubMedCrossRef

21.

Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Mali WP, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025–34.PubMedCrossRef

22.

Elschot M, Smits ML, Nijsen JF, Lam MG, Zonnenberg BA, van den Bosch MA, et al. Quantitative Monte Carlo-based holmium-166 SPECT reconstruction. Med Phys. 2013;40:112502.PubMedCrossRef

23.

Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Huijbregts JE, et al. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. J Exp Clin Cancer Res. 2010;29:70.PubMedCentralPubMedCrossRef

24.

Salem R, Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Ibrahim S, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Intervent Radiol. 2007;10:12–29.CrossRef

25.

Xiao JB, de Wit TC, Staelens SG, Beekman FJ. Evaluation of 3D Monte Carlo-based scatter correction for Tc-99m cardiac perfusion SPECT. J Nucl Med. 2006;47:1662–69.PubMed

26.

de Wit TC, Xiao J, Nijsen JF, van het Schip FD, Staelens SG, van Rijk PP, et al. Hybrid scatter correction applied to quantitative holmium-166 SPECT. Phys Med Biol. 2006;51:4773–87.PubMedCrossRef

27.

Bol GH, Kotte AN, van der Heide UA, Lagendijk JJ. Simultaneous multi-modality ROI delineation in clinical practice. Comput Methods Prog Biomed. 2009;96:133–40.CrossRef

28.

de Jong HW, Beekman FJ. Rapid simulation of downscatter in non-uniform media. Phys Med Biol. 2001;46:621–35.PubMedCrossRef

29.

de Jong HWAM, Wang WT, Frey EC, Viergever MA, Beekman FJ. Efficient simulation of SPECT down-scatter including photon interactions with crystal and lead. Med Phys. 2002;29:550–60.PubMedCrossRef

30.

van Dyk J, Keane TJ, Rider WD. Lung density as measured by computerized-tomography – implications for radiotherapy. Int J Radiat Oncol Biol Phys. 1982;8:1363–72.PubMedCrossRef

31.

Vente MA, Nijsen JF, de Wit TC, Seppenwoolde JH, Krijger GC, Seevinck PR, et al. Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L-lactic acid) microspheres in healthy pigs. Eur J Nucl Med Mol Imaging. 2008;35:1259–71.PubMedCentralPubMedCrossRef

32.

Sabet A, Ahmadzadehfar H, Muckle M, Haslerud T, Wilhelm K, Biersack HJ, et al. Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. J Nucl Med. 2011;52:1063–7.PubMedCrossRef

33.

Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37S–61S.PubMed

34.

Bult W, Vente MAD, Zonnenberg BA, van het Schip AD, Nijsen JFW. Microsphere, radioembolization of liver malignancies: current developments. Q J Nucl Med Mol Imaging. 2009;53:325–35.PubMed

35.

Taplin GV, MacDonald NS. Radiochemistry of macroaggregated albumin and newer lung scanning agents. Semin Nucl Med. 1971;1:132–52.PubMedCrossRef

36.

Zolle I, Bremer PO, Janoki G. Monographs of 99mTc pharmaceuticals. In: Zolle I, ed. Technetium-99m pharmaceuticals. Berlin: Springer; 2007. p. 173–337.CrossRef

37.

Zielhuis SW, Nijsen JF, De RR. Production of GMP-grade radioactive holmium loaded poly(L-lactic acid) microspheres for clinical application. Int J Pharm. 2006;311:69–74.PubMedCrossRef

38.

Pasciak AS, Erwin WD. Effect of voxel size and computation method on Tc-99m MAA SPECT/CT-based dose estimation for Y-90 microsphere therapy. IEEE Trans Med Imaging. 2009;28:1754–8.PubMedCrossRef

39.

Elschot M, Nijsen JF, Dam AJ, de Jong HW. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6:e26174.PubMedCentralPubMedCrossRef

40.

Willowson K, Bailey DL, Baldock C. Quantifying lung shunting during planning for radio-embolization. Phys Med Biol. 2011;56:N145–52.PubMedCrossRef

41.

Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of (99m)Tc-MAA SPECT/CT liver perfusion imaging in treatment planning for (90)Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51:1206–12.PubMedCrossRef

42.

Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82:401–7.PubMedCrossRef

Titel: 99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Ho-microspheres
verfasst von: Mattijs Elschot
Johannes F. W. Nijsen
Marnix G. E. H. Lam
Maarten L. J. Smits
Jip F. Prince
Max A. Viergever
Maurice A. A. J. van den Bosch
Bernard A. Zonnenberg
Hugo W. A. M. de Jong
Publikationsdatum: 01.10.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2784-9

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson’s disease

Mycotic aneurysm of the superior mesenteric artery and other sequelae of prosthetic valve endocarditis on 18F-FDG PET/CT

Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

11C-ORM-13070, a novel PET ligand for brain α2C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men

18F-fluorodeoxyglucose positron emission tomography combined with whole-body computed tomographic angiography in critically ill patients with suspected severe sepsis with no definite diagnosis